Synthesis and Antitumor Activity of a Series of [2-Substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) Complexes

Journal of Medicinal Chemistry

Volumn 37, Issue 10, 1994, Pages 1471-1485

  Kim, Dae Kee ^a,b,c,d   Kim, Ganghyeok ^a,b,c,d   Gam, Jongsik ^a,b,c,d   Cho, Yong Baik ^a,b,c,d   Kim, Hun Taek ^a,b,c,d   Tai, Joo Ho ^a,b,c,d   Kim, Key H ^a,b,c,d   Hong, Weon Seon ^a,b,c   Park, Jae Gahb ^a,b,c,e  

^a Sunkyong Industries   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Sunkyong Industries   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; MIBOPLATIN; NEDAPLATIN; PLATINUM [4,5 BIS(AMINOMETHYL) 1,3 DIOXOLANE 2 SPIRO 1' CYCLOHEXANE] GLYCOLATE; PLATINUM [4,5 BIS(AMINOMETHYL) 1,3 DIOXOLANE 2 SPIRO 1' CYCLOPENTANE] GLYCOLATE; PLATINUM [4,5 BIS(AMINOMETHYL) 2 ETHYL 1,3 DIOXOLANE] GLYCOLATE; PLATINUM [4,5 BIS(AMINOMETHYL) 2 ISOPROPYL 1,3 DIOXOLANE] GLYCOLATE; PLATINUM [4,5 BIS(AMINOMETHYL) 2 METHYL 1,3 DIOXOLANE] MALONATE; PLATINUM COMPLEX; SEBRIPLATIN; TETRAPLATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SOLUBILITY; DRUG SYNTHESIS; FAST ATOM BOMBARDMENT MASS SPECTROMETRY; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; UREA NITROGEN BLOOD LEVEL;

ANIMAL; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN; KIDNEY DISEASES; LEUKEMIA L1210; MALE; MICE; MICE, INBRED DBA; MICE, INBRED ICR; ORGANOPLATINUM COMPOUNDS; SOLUBILITY; STEREOISOMERISM; STOMACH NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0028275932     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00036a013     Document Type: Article

References (60)

1. Rosenberg, B.; VanCamp, L.; Trosko, J. E.; Mansour, V. H. Platinum Compounds: a New Class of Potent Antitumor Agents. Nature 1969, 222, 385-386
2. Carter, S. K. Cisplatin-Past, Present and Future. In Platinum Coordination Complexes in Cancer Chemotherapy; Hacker, M. P., Douple, E. B., Krakoff, I. H., Eds.; Martinus Nijhoff Publishing: Boston, 1984; pp 359-376
3. Durant, J.R. Cisplatin: a Clinical Overview. In Cisplatin Current Status and New Developments; Prestayko, A. W., Crooke, S. T., Carter, S. K., Eds.; Academic Press, Inc.: New York, 1980; pp 317-321
4. Loehrer, P. J.; Einhorn, L. H. Drugs Five Years Later. Cisplatin. Ann. Intern. Med. 1984, 100, 704-713
5. Einhorn, L. H.; Donohue, J. cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer. Ann. Intern. Med. 1977, 87, 293-298
6. Ozols, R. F.; Young, R. C. Chemotherapy of Ovarian Cancer. Semin. Oncol. 1984, 11, 251-263
7. Wiltshaw, E. Phase II Study of cis-Dichlorodiammineplatinum(II) (NSC-119875, CACP) in Advanced Adenocarcinoma of the Ovary. Cancer Treat. Rep. 1976, 60, 55-60
8. Soloway, M. S. cis-Dichlorodiammmeplatinum(II) (DDP) in Advanced Bladder Cancer. J. Urol. 1978, 120, 716-719
9. Florentino, M. V.; Ghiotto, C. Platinum, the Synergistic Drug: from Clinical Evidence to Laboratory Suggestions. In Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy; Nicolini, M., Ed.; Martinus Nijhoff Publishing: Boston, 1988; pp 415-435
10. Choksi, A.; Hong, W. K. Chemotherapy of Head and Neck Cancer. In Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy; Nicolini, M., Ed.; Martinus Nijhoff Publishing: Boston, 1988; pp 375-385
11. Paccagnella, A.; Favaretto, G.; Florentino, M. V. Chemotherapy of Lung Cancer. In Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy; Nicolini, M., Ed.; Martinus Nijhoff Publishing: Boston, 1988; pp 394-414
12. Wagener, D. J.; Yap, S. H.; Wobbes, T.; Burghouts, J. T.; van Dam, F. E.; Hillen, H. F.; Hoogendoorn, G. J.; Scheerder, H.; van der Vegt, S. G. Phase II Trial of 5-Fluorouracil, Adriamycin and Cisplatin (FAP) in Advanced Gastric Cancer. Cancer Chemother. Pharmacol. 1985, 15, 86-87
13. Von Hoff, D. D.; Schilsky, R.; Reichert, C. M.; Reddick, R. L.; Rozencweig, M.; Young, R. C.; Muggia, F. M. Toxic Effects of cis-Dichlorodiammineplatinum(II) in Man. Cancer Treat. Rep. 1979, 63, 1527-1531
14. Krakoff, I. H. Nephrotoxicity of cis-Dichlorodiammineplatinum-(II). Cancer Treat. Rep. 1979, 63, 1523-1525
15. Ishibiki, K.; Kumai, K.; Kodaira, S.; Abe, O.; Yamamoto, K.; Oochi, T.; Fukaya, Y.; Kimura, K.; Takamatsu, K.; Ootsuka, E.; Sakabe, T.; Nishiyama, K.; Sekizawa, Y.; Ooide, N.; Tsuchiya, S.; Togo, S.; Ishida, T.; Mishima, Y.; Ogoshi, K.; Mitomi, T. Phase II Study with Cisplatin in Advanced Stomach and Colon Carcinoma. Jpn. J. Cancer Chemother. 1989, 16, 3185-3193
16. Ozols, R. F. Pharmacologic Reversal of Drug Resistance in Ovarian Cancer. Semin. Oncol. 1985, 12 (Suppl. 4), 7-11
17. Hong, W.-S.; Saijo, N.; Sasaki, Y.; Minato, K.; Nakano, H.; Nakagawa, K.; Fujiwara, Y.; Nomura, K.; Twentyman, P. R. Establishment and Characterization of Cisplatin-resistant Sublines of Human Lung Cancer Lines. Int. J. Cancer 1988, 41, 462-467
18. Inoue, K.; Mukaiyama, T.; Mitsui, I.; Ogawa, M. In Vitro Evaluation of Anticancer Drugs in Relation to Development of Drug Resistance in the Human Tumor Clonogenic Assay. Cancer Chemother. Pharmacol. 1985, 15, 208-213
19. Burchenal, J. H.; Kalaher, K.; Dew, K.; Lokys, L. Rationale for Development of Platinum Analogs. Cancer Treat. Rep. 1979, 63, 1493-1498
20. Connors, T. A.; Cleare, M. J.; Harrap, K. R. Structure-Activity Relationships of the Antitumor Platinum Coordination Complexes. Cancer Treat. Rep. 1979, 63, 1499-1502
21. Wilkinson, R.; Cox, P. J.; Jones, M.; Harrap, K. R. Selection of Potential Second Generation Platinum Compounds. Biochimie 1978, 60, 851-857
22. Brown, D. B.; Khokhar, A. R.; Hacker, M. P.; Lokys, L.; Burchenal, J. H.; Newman, R. A.; McCormack, J. J.; Frost, D. Synthesis and Antitumor Activity of New Platinum Complexes. J. Med. Chem. 1982, 25, 952-956
23. Lelieveld, P.; Van der Vijgh, W. J. F.; Veldhuizen, R. W.; Van Velzen, D.; VanPutten, L. M.; Atassi, G.; Danguy, A. Preclinical Studies on Toxicity, Antitumor Activity and Pharmacokinetics of Cisplatin and Three Recently Developed Derivatives. Eur. J. Cancer Clin. Oncol. 1984, 20, 1087-1104
24. Carter, S. K.; Canetta, R.; Rozencweig, M. Carboplatin: Future Directions. Cancer Treat. Rev. 1985, 12 (Suppl. A), 145-152
25. Harrap, K. R. Preclinical Studies Identifying Carboplatin as a Visible Cisplatin Alternative. Cancer Treat. Rev. 1985, 12 (Suppl. A), 21-33
26. Calvert, A. H.; Harland, S. J.; Newell, D. R.; Siddik, Z. H.; Jones, A. C.; McElwain, T. J.; Raju, S.; Wiltshaw, E.; Smith, I. E.; Baker, J. M.; Peckham, M. J.; Harrap, K. R. Early Clinical Studies with cis-Diammine-1,1-cyclobutanedicarboxylate Platinum(II). Cancer Chemother. Pharmacol. 1982, 9, 140-147
27. Foster, B. J.; Clagett-Carr, K.; Leyland-Jones, B.; Hoth, D. Results of NCI-Sponsored Phase I Trials with Carboplatin. Cancer Treat. Rev. 1985, 12 (Suppl. A), 43-49
28. Canetta, R.; Rosencweig, M.; Carter, S. K. Carboplatin: the Clinical Spectrum to Date. Cancer Treat. Rev. 1985, 12 (Suppl. A), 125-136
29. Gore, M.; Fryatt, I.; Wiltshaw, E.; Dawson, T.; Robinson, B.; Calvert, A. Cisplatin/Carboplatin Cross-Resistance in Ovarian Cancer. Br. J. Cancer 1989, 60, 767-769
30. Kikuchi, Y.; Iwano, I.; Miyauchi, M.; Kita, T.; Sugita, M.; Tenjin, Y.; Nagata, I. Possible Mechanisms of Resistance to cis-Diamminedichloroplatinum(II) of Human Ovarian Cancer Cells. Jpn. J. Cancer Res. 1990, 81, 701-706
31. Anderson, W. K.; Quagliato, D. A.; Haugwitz, R. D.; Narayanan, V. L.; Wolpert-DeFilippes, M. K. Synthesis, Physical Properties, and Antitumor Activity of Tetraplatin and Related Tetrachloroplatinum(IV) Stereoisomers of 1,2-Diaminocyclohexane. Cancer Treat. Rep. 1986, 70, 997-1002
32. McPherson, R. A.; Roh, J. K.; Komanduri, K.; Mhatre, R.; Wooley, P. V.; Rahman, A. Toxicological Evaluation of Tetraplatin (NSC 363812) in Comparison to CDDP. Proc. Am. Assoc. Cancer Res. 1986, 27, Abst. 1153
33. Totani, T.; Aono, K.; Komura, M.; Adachi, Y. Synthesis of (Glycolato-O,O′)diammineplatinum(II) and Its Related Complexes. Chem. Lett. 1986, 429-432
34. Fukuda, M.; Shinkai, T.; Eguchi, K.; Sasaki, Y.; Tamura, T.; Ohe, Y.; Kojima, A.; Oshita, F.; Hara, K.; Saijo, N. Phase-II Study of (Glycolato-O,O′)diammineplatinum(II), a Novel Platinum Complex, in the Treatment of Non-Small-Cell Lung Cancer. Cancer Chemother. Pharmacol. 1990, 26, 393-396
35. Nowatari, H.; Kuroda, Y.; Hayami, H.; Okamoto, K.; Ekimoto, H.; Takahashi, K. Synthesis and Antitumor Activity of Alkyl-1,4- butanediamine Pt(II) Complexes Having Seven-Membered Ring Structure. Chem. Pharm. Bull. 1989, 37, 2406-2409
36. Yamaue, H.; Tanimura, H.; Tani, M.; Iwahashi, M.; Tsunoda, T.; Inoue, M. In Vitro Antitumor Activity of a New Platinum Analogue, NK 121 against Fresh Human Tumor Cells and Established Tumor Cell Lines by Succinate Dehydrogenase Inhibition Test. Chemotherapy (Tokyo) 1990, 38, 780-789
37. Morikawa, K.; Honda, M.; Endoh, K.; Matsumoto, T.; Akamatsu, K.; Mitsui, H.; Koizumi, M. Synthesis, Antitumor Activity, and Nephrotoxicity of the Optical Isomers of 2-Aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum(II). J. Pharm. Sci. 1991, 80, 837-842
38. Matsumoto, T.; Endo, K.; Akamatsu, K.; Kamisango, K.; Mitsui, H.; Koizumi, K.; Morikawa, K.; Koizumi, M.; Matsuno, T. Comparison of the Antitumor Effects and Nephrotoxicity-Inducing Activities of Two New Platinum Complexes, (-)-(R)-2-Aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum(II) Monohydrate, and Its Enantiomeric Isomer. Br. J. Cancer 1991, 64, 41-46
39. Kamisango, K.; Matsumoto, T.; Akamatsu, K.; Morikawa, K.; Tashiro, T.; Koizumi, K. Antitumor Activity and Cellular Accumulation of a New Platinum Complex, (-)-(R)-2-Aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum(II) Monohydrate, in Cisplatin-sensitive and -resistant Murine P388 Leukemia Cells. Jpn. J. Cancer Res. 1992, 83, 304-311
40. Pasini, A.; Zunino, F. New Cisplatin Analogues On the Way to Better Antitumor Agents. Angew. Chem., Int. Ed. Engl. 1987, 26, 615-624
41. Kaplan, M. A.; Granatek, A. P. Salts of 2-Hydroxymalonato Diammine Platinum(II) Compounds, Process for Preparing Said Compounds and Pharmaceutical Compositions Containing Said Compounds. Eur. Pat. 41,644 A2, 1981
42. Takahashi, K.; Okamoto, K.; Minamide, S.; Yamashita, T. Activity and Toxicity of a New Platinum Complex (NK-121), cis-1,1-Cyclobutanedicarboxylato-(2R)-2-methyl-1,4-butanediamine Platinum(II). Proc. Am. Assoc. Cancer Res. 1988, 29, 339
43. Kraker, A. J.; Moore, C. W.; Leopold, W. R.; Takahashi, K. Preclinical Characterization of the in vitro and in vivo Activity of [1,1′-Cyclobutanedicarboxylato(2-)-O,O′] (2-Methyl-1,4-butanediamine-N,N′)Pt (NK-121/Cl-973). Proc. Am. Assoc. Cancer Res. 1988, 29, 344
44. Haines, A. H.; Morley, C.; Murrer, B. A. Analogues of Cisplatin Derived from Diaminodideoxytetritols. Synthesis and Activity against the ADJ/PC6 Plasmacytoma in Mice. J. Med. Chem. 1989, 32, 742-745
45. Bitha, P.; Carvajal, S. G.; Citarella, R. V.; Delos Santos, E. F.; Durr, F. E.; Hlavka, J. J.; Lang, Jr., S. A.; Lindsay, H. L.; Thomas, J. P.; Wallace, R. E., Lin, Y. a New Family of Water-Soluble, Third Generation Antitumor Platinum Complexes. J. Med. Chem. 1989, 32, 2063-2067
46. Noji, M.; Okamoto, K.; Kidani, Y. Relation of Conformation to Antitumor Activity of Platinum(II) Complexes of 1,2-Cyclohexanediamine and 2-(Aminomethyl)cyclohexylamine Isomers against Leukemia P388. J. Med. Chem. 1981, 24, 508-515
47. Kidani, Y.; Inagaki, K.; Iigo, M.; Hoshi, A.; Kuretani, K. Antitumor Activity of 1,2-Diaminocyclohexane Platinum Complexes against Sarcoma-180 Ascites Form. J. Med. Chem. 1978, 21, 1315-1318
48. Totani, T.; Aono, K.; Adachi, Y.; Komura, M.; Shiratori, O.; Sato, K. Bidentate Hydroxycarboxylic Acid Platinum(II) Complexes with Antitumor Activity. In Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy; Nicolini, M., Ed.; Martinus Nijhoff Publishing: Boston, 1988 pp 744-748
49. Miyamoto, T. K.; Okude, K.; Maeda, K.; Ichida, H.; Sasaki, Y.; Tashiro, T. Syntheses, Spectroscopic Properties, Crystal Structures, and Antitumor Activities of the Optically Isomeric Mandelate Chelates, Mandelato(trons-1,2-diaminocyclohexane) platinum(II). Bull. Chem. Soc. Jpn. 1989, 62, 3239-3246
50. Feit, P. W. 1,4-Bismethanesulfonates of the Stereoisomeric Butanetetraols and Related Compounds. J. Med. Chem. 1964, 7, 14-17
51. Park, J.-G.; Frucht, H.; LaRocca, R. V.; Bliss, Jr., D. P.; Kurita, Y.; Chen, T.-R.; Henslee, J. G.; Trepel, J. B.; Jensen, R. T.; Johnson, B. E.; Bang, Y.-J.; Kim, J.-P.; Gazdar, A. F. Characteristics of Cell Lines Established from Human Gastric Carcinoma. Cancer Res. 1990, 50, 2773-2780
52. Anonymous. Ministry of Health and Social Affairs. One Year's Report for Cancer Registry Programme in the Republic of Korea. July 1, 1985-June 30, 1986. J. Korean Cancer Assoc. 1987, 19, 131-258
53. Mettlin, C. Epidemiologic Studies in Gastric Adenocarcinoma. In Gastric Cancer, Douglass, H. O., Ed.; Churchill Livingstone: New York, 1988; pp 1-25
54. Carmichael, J.; DeGraff, W. G.; Gazdar, A. F.; Minna, J. D.; Mitchell, J. B. Evaluation of a Tetrazolium-Based Semiautomated Colorimetric Assay: Assessment of Chemosensitivity Testing. Cancer Res. 1987, 47, 936-942
55. Mossman, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assay. J. Immunol. Methods 1983, 65, 55-63
56. Rose, W. C.; Schurig, J. E.; Huftalen, J.B.; Bradner, W. T. Antitumor Activity and Toxicity of Cisplatin Analogs. Cancer Treat. Rep. 1982, 66, 135-146
57. Geran, R. I.; Greenberg, N. R.; Macdonald, M. M.; Schumacher, A. M.; Abbott, B. J. Protocols for Screening Chemical Agents and Natural Products against Animal Tumors and Other Biological Systems. Cancer Chemother. Rep. Part 3 1972, 3, 1-103
58. Eastman, A.; Illenye, S. Murine Leukemia L1210 Cell Lines with Different Patterns of Resistance to Platinum Coordination Complexes. Cancer Treat. Rep. 1984, 68, 1189-1190
59. Burchenal, J. H.; Kalaher, K.; Toole, T.; Chisholm, J. Lack of Cross-Resistance between Certain Platinum Coordination Compounds in Mouse Leukemia. Cancer Res. 1977, 37, 3455-3457
60. Tallarida, R. J.; Murray, R. B. Manual of Pharmacologic Calculations with Computer Programs; Springer-Verlag: New York, 1987; pp 31-35